help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Holzenberger, M.
Right arrow Articles by Le Bouc, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holzenberger, M.
Right arrow Articles by Le Bouc, Y.
Endocrinology Vol. 142, No. 10 4469-4478
Copyright © 2001 by The Endocrine Society


ARTICLES

Experimental IGF-I Receptor Deficiency Generates a Sexually Dimorphic Pattern of Organ-Specific Growth Deficits in Mice, Affecting Fat Tissue in Particular

Martin Holzenberger1, Ghislaine Hamard, Randa Zaoui, Patricia Leneuve, Bertrand Ducos, Caroline Beccavin, Laurence Périn and Yves Le Bouc

INSERM, U-515, Hôpital Saint-Antoine (M.H., R.Z., P.L., B.D., C.B., L.P., Y.L.B.), 75571 Paris, France; and INSERM, U-380, Faculté de Médecine Cochin-Port Royal (G.H.), 75014 Paris, France

Address all correspondence and requests for reprints to: Dr. Martin Holzenberger, INSERM, U-515, Hôpital Saint Antoine, 75571 Paris Cedex 12, France. E-mail: holzenberger{at}st-antoine.inserm.fr


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Reduced IGF type I receptor levels diminish postnatal growth rate and adult body weight in mice. Here, we studied the impact of experimental IGF receptor deficiency on tissue-specific growth by Cre-lox-mediated dosage of a floxed IGF-IR gene. We generated mice with a wide spectrum of receptor deficiency (5–82%), and separated them into two groups with either strong (>=50%) IGF-IR deficiency (XS mice) or moderate deficiency (<50%, M mice). The growth of XS mice was significantly retarded from 3 wk after birth onward, with respect to M littermates. This effect was twice as strong in males as in females. Growth deficits persisted throughout adult life, and at 10–12 months, most organs and tissues showed specific weight defects. Skin, bone and connective tissue, muscle, spleen, heart, lung, and brain were the most severely affected organs in the XS males. With the exception of muscle and spleen, the same tissues were also significantly reduced in size in females, although to a lesser extent. The most severe growth defect, however, concerned adipose tissue. Fat pad size in XS males was only 29% (females, 44%) of M mice. The estimated number of adipocytes in XS male fat pads was only 21% that of M males (XS female, 27%). Lipid content per cell was significantly higher in XS adipocytes, whereas plasma glucose and insulin levels were low in XS males. Thus, IGF type I receptor deficiency produced mice with disproportionate postnatal organ growth, and these effects depended strongly on sex. A marked reduction in IGF-IR levels resulted in a major defect in adipose tissue.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
IGFs ARE IMPORTANT regulators of embryonic and postnatal growth in vertebrates. IGF-II is involved principally in embryonic growth (1), whereas its homolog, IGF-I, is involved in embryonic and postnatal growth (2). Both ligands signal via the same tyrosine kinase receptor (IGF-IR) (3, 4). IGF-I and IGF-IR are essential mediators of GH activity in the juvenile animal, and are still present at significant levels in many tissues in the adult. Current efforts try to elucidate the tissue-specific roles of IGF signaling in vivo, using conditional genetic approaches (5, 6, 7). We applied Cre-lox technology (8, 9, 10) to the IGF-IR gene to identify major IGF target cells and organs and to dissect the receptor function systematically (11).

Studies of the classical IGF-IR knockout (KO) suggested that during embryonic development, lung, muscle and skin depend more strongly on IGFs than other organs (12, 13). However, as classical IGF-IR KO mice invariably die at birth, it has been difficult to extend such studies to postnatal growth and development. The classical KO of IGF-I produces a less severe developmental retardation, and depending on genetic background, the complete, constitutive loss of IGF-I function is not necessarily lethal (14, 15, 16, 17). This model is of particular interest because some of the IGF signaling is maintained during embryonic development through the action of IGF-II, such that these mice become gradually IGF deficient toward the end of embryonic development and the beginning of postnatal life, when endogenous IGF-II is down-regulated. Interestingly, in juvenile IGF-I-/- mice, the growth of lung tissue is affected more than that of liver and kidney (17). From these and other findings, it was deduced that musculo-skeletal compartments may be major targets for postnatal action of IGF-I. However, it is a complex task to assess the tissue-specific role of IGFs, because these growth factors act via both paracrine and endocrine mechanisms. It was shown that tissue-specific overproduction of IGF-I in transgenic animals increases local growth (18, 19, 20). In addition, liver-specific IGF-I gene KO in mice (6) showed that most, if not all, postnatal and pubertal IGF-I-mediated growth can be achieved through tissue-derived (nonhepatic) IGF-I as the predominant postnatal source of IGF-I. The continuation of this and other work, in particular the use of tissue-specific gain and loss of function models, may show in the future which of the many cell type-specific effects of IGFs identified in in vitro studies are relevant in vivo.

By gene targeting we previously produced a hypomorphic IGF-I receptor allele (a so-called knockdown, with partially reduced expression of IGF-IR) and showed that reduced availability of the IGF-I receptor slows down postnatal growth (21). The pubertal growth spurt in these mice is smaller than that in normal mice and resulted in a durable growth defect despite IGF-I up-regulation and IGF-binding protein-4 (IGFBP-4) down-regulation. This hypomorphic gene mutation affected total body weight more than the weight of individual organs (e.g. thoracic organs, brain, or bone). We concluded that other body compartments not evaluated in that study, such as skin or muscle, would probably show more potent effects in response to IGF-I receptor deficiency. To identify these compartments, we here produced a mouse model with strongly and ubiquitously impaired IGF type I receptor function, employing a gene dosage strategy (22, 23). We also generated a Cre transgenic mouse that produces a useful pattern of mosaic-early embryonic-ubiquitous gene deletion (MeuCre). By crossing this line with mice harboring the floxed hypomorphic IGF-IR allele, we were able to generate mice with very low IGF-I receptor levels. Under these conditions, sexually dimorphic patterns of pubertal growth retardation were observed, and tissues and organs with significant growth deficits were identified.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Animals
The MeuCre transgenic line was produced by standard pronuclear injection (24). MeuCre uses a tet-operon/cytomegalovirus-minimal promoter controlling expression of the Cre cDNA (25). Probably due to positional effects, the MeuCre transgenic line produces Cre constitutively during a short period of early embryonic development. This early embryonic Cre expression results in mosaic Cre-lox recombination, deleting, on the average, 40% of the floxed alleles. MeuCre-mediated recombination efficiency differs little between tissues in a given individual (see Table 1Go), indicating that it occurs largely before organogenesis. Later, this recombination pattern is transmitted to all developing tissues. We found that recombination efficiency differs considerably between animals; the average Cre recombination efficiency measured in tail DNA (n = 24) is 39.9 ± 21.5% (±SD; range, 6.3–85%). This interindividual variability increases the chances for producing a large spectrum of degrees of gene expression deficiency in the chosen experimental setup. MeuCre mice were mated with IGF-IRneolox mice (21) to produce Cre-lox double transgenics, which were then mated with homozygous IGF-IRneolox mice to produce the F2 generation (Fig. 1Go, A and B) (26).


View this table:
[in this window]
[in a new window]
 
Table 1. Average profile of the efficiency of IGF-IR excision by MeuCre in different tissues

 


View larger version (43K):
[in this window]
[in a new window]
 
Figure 1. Production of mice with various degrees of IGF-IR deficiency. A, Targeted mutation: exon 3 (e3) of the WT IGF-IR gene was replaced by a floxed exon 3 ({blacktriangleright}, loxP). A neomycin resistance cassette (neo), equipped with a third loxP site was cointroduced into intron 2. This created the hypomorphic IGF-IRneolox allele. B, Breeding scheme for gene dosage: MeuCre transgenic mice mated with IGF-IRneolox mice produced double transgenic MeuCre/IGF-IRneolox (F1). These were mated with homozygous IGF-IRneolox, producing the F2 mice. These F2 mice comprised six different genotypes that produced a large range of receptor deficiency (indicated in percentage of WT). Using MeuCre and IGF-IRneolox on C57BL/6 genetic background in F0 matings, and homozygous IGF-IRneolox mice on 129/Sv background in F1 matings, we obtained C57BL/6–129/Sv first generation hybrids in F2. C, Representative F2 genomic Southern blots for each genotype. In a HincII tail DNA digest, the WT allele and the four possible forms of the targeted allele were detected as discrete bands (see Materials and Methods for details). MeuCre-mediated excision occurs at early embryonic stages in all tissues, including germline cells. Thus, some F2 mice received from their MeuCre/IGF-IRneolox parent (B6) an IGF-IR KO allele. The other allele was always inherited as IGF-IRneolox (NL) allele. Different alleles produced different amounts of receptor compared to WT: IGF-IRneolox, 60% (21 ); {Delta}neo, 100% (21 ) (a restored-to-WT mutation); {Delta}ex3, 0%; and KO, 0% (see Fig. 2Go). 129, Genetic background 129/SvPas; B6, C57BL/6 background; HcII, HincII site; MWM, DNA mol wt marker; MeuCre, presence (+) or absence (-) of MeuCre; neo, neomycin resistance cassette.

 
Mice were housed in standard conditions (25 C; 12-h light, 12-h dark cycle; standard rodent diet containing 5% lipids and water ad libitum). Pups were weaned at 25 d. All animal experiments were conducted in accordance with the institutional guidelines for the care and use of animals. Body weight was measured ±0.1 g at 3, 6, and 9 wk. Blood samples (100–200 µl) were taken from adults by retroorbital puncture using Pasteur pipettes rinsed with 0.5 M EDTA and by cardiac puncture at the time of dissection. Plasma samples were stored at -20 C. We randomly selected 92 mice from the total of 126 F2 mice. These mice represented all 6 possible genotypes from both sexes and were killed before dissection at 10–12 months of age. The wet weight of organs and tissues was determined on a calibrated balance (e = 0.1 mg; Denver Instruments, Arvada, CO). Data were handled using Excel (Microsoft Corp., Redmond, WA) and analyzed with StatView (Abacus Concepts, Inc., Berkeley, CA).

Details of the anatomical dissection
The skin was removed, with the exception of the tail tip and feet. The brain was separated from spinal cord and removed. Limb muscles were sectioned at their proximal insertions, limbs were removed at their proximal joints, and feet were removed (bones accounted for about 5% of limb weight; the rest was muscle). The genital fat pad, also termed the inguinal or abdominal fat pad, and the major abdominal and thoracic organs were prepared. Blood vessels were sectioned at the organ hilus (kidney and liver). The large blood vessels of the heart were cut at the atrium, and coagulated blood was removed from the ventricles. The weight of the rest (difference between body weight before death and the sum of the weights of the organs and tissues) corresponded essentially to the gastrointestinal tract, bladder, female reproductive organs, and uncollected blood. Feet and any connective tissue removed during the dissection were added to the carcass, which comprised essentially the skeleton and connective tissue from the body and the head.

DNA preparation
DNA was prepared using standard procedures (27). Tail biopsy samples (5 mm) from 10-d-old animals or tissue samples (50 mg; fat tissue, 200 mg) from adult animals were digested overnight with proteinase K (Eurobio, Les Ulis, France) and centrifuged, and the supernatant was mixed with an equal volume of isopropanol. The resulting precipitate was washed with 75% ethanol, dried, and resuspended in 10 mmol Tris, pH 8.0. For quantitative purposes, deoxyribonuclease-free ribonuclease (Roche Molecular Biochemicals, Basel, Switzerland) was added, and phenol/chloroform extractions were performed before precipitation. The amount of DNA extracted from weighed, representative tissue fractions was determined by UV spectrophotometry (Genesys 5, Spectronic Instruments, Rochester, NY), and expressed in microgram per µl. Two DNA extractions were performed per animal, and ODs were determined twice per extraction.

To calculate cell size from DNA content we estimated the mouse genome to 3.5 Gbp, so that 1 µg double stranded purified DNA corresponded to 2.6 x 105 extracted cell nuclei. The specific weight ({rho}) of tissues was estimated to be 1 mg/µl, with the exception of that for adipose tissue, which was estimated to be 0.8 mg/µl. The average cell volume (V) was calculated using V (fl) = W (mg) x ({rho} (mg/µl) x DNA (µg) x 2.6 x 105 (µg-1))-1, with W being the weight of the extracted tissue fraction. To quantitatively evaluate the individual fat cell compartment, the number of adipocytes was estimated dividing the adipose tissue volume by the average adipocyte volume.

Southern and dot blotting
DNA (8 µg) from each mouse was digested with HincII, subjected to electrophoresis in a 1% agarose gel, transferred to nylon membranes (Hybond+, Amersham Pharmacia Biotech, Little Chalfont, UK) by capillary action, and hybridized with a genomic probe (radiolabeled using Rediprime, Amersham Pharmacia Biotech). The probe recognized the 750-bp intronic region directly upstream from the inserted neomycin resistance cassette. We detected a 2.4-kb wild-type IGF-IR genomic fragment, a 4.5-kb targeted allele with floxed neo-cassette and exon 3 (neolox (NL)), a 3.6-kb exon 3-excised ({Delta}ex3) allele, a 2.5-kb neo-cassette excised ({Delta}neo) allele, and a 1.7-kb total excision (KO) allele. The size of the loxP insertions (40–50 bp) must be added to the fragment sizes indicated in Fig. 1Go. Membranes were placed against x-ray film (Curix RP-2, Agfa-Gevaert, Mortsel, Belgium) for 1–4 d at -80 C with amplifying screens. To quantify individual receptor deficiency from genomic data, blots were exposed to phosphorimager screens and analyzed using a STORM 850 PhosphorImager (Molecular Dynamics, Inc., Sunnyvale, CA) and ImageQuant. For dot-blotting, DNA (10 µg) was denatured by heating, transferred to nylon membranes, and probed with 1.1 kb Cre cDNA.

Receptor binding assays
Recombinant human IGF-I (rhIGF-I; GroPep Pty. Ltd., Adelaide, Australia) was labeled with 125I (Amersham Pharmacia Biotech) using the chloramine-T method (SA, ~100 µCi/µg). All chemicals were obtained from Sigma (St. Louis, MO). Crude membranes were prepared from whole brain as previously described (28). After decapitation, brains were quickly removed and homogenized. The homogenate was centrifuged twice at 4 C. The pellet was resuspended, and the suspension was immediately used for binding assays. Proteins were measured using the bicinchoninic acid protein assay from Pierce Chemical Co. (Rockford, IL). Binding assays were performed as previously described (21) in 0.5 ml 50 mM Tris-HCl buffer containing the membrane preparation (300 µg protein) and 15–20 pM [125I]rhIGF-I. Nonspecific binding was determined in the presence of 200 nM rhIGF-I.

IGF-I assay
Plasma samples (10–25 µl) were incubated in 0.01 M HCl for 30 min at room temperature and subjected to ultrafiltration through Centricon 30 columns (Amicon, Millipore Corp., Bedford, MA). The ultrafiltrate was lyophilized, resuspended in 0.1 M phosphate buffer and 1 mg/ml BSA, pH 7.4, and incubated for 3 d with [125I]rhIGF-I (3000 cpm/tube) and a polyclonal antihuman IGF-I antibody (final dilution, 1:120,000; a gift from J. Closset, CHU, Liège, Belgium), that cross-reacts with murine IGF-I (29, 30). Samples were tested at four concentrations, each in duplicate (30). After incubation, free and bound IGFs were separated using albumin-coated charcoal as previously described (31). The detection threshold of the assay was 2 ng/ml plasma. There was 5% intraassay variation and 10% interassay variation.

Western ligand blotting of IGFBPs
Plasma samples (3 µl/animal) were subjected to 12.5% nonreducing PAGE (32). Proteins were electrotransferred onto nitrocellulose membranes and incubated with [125I]IGF-I and [125I]IGF-II (500,000 cpm each). Membranes were washed and placed against x-ray film (Agfa-Gevaert) at -80 C. Pooled normal samples of human and mouse origin were included on each gel as standards. Western ligand blots were quantified using phosphorimager technology and ImageQuant software (Molecular Dynamics, Inc.). Individual results were compared with standard mouse samples on the same blot and normalized. Numerical results on circulating levels of IGFBP-1 to -4 were statistically evaluated using the Mann-Whitney test.

Histology and blood biochemistry
Genital fat pads from males and females were quickly frozen over liquid nitrogen and embedded in Cryo-M-Bed (Bright, Huntingdon, UK). Cryosections (-30 C, 15 µm) were prepared on SuperFrost Plus slides (Menzel-Gläser, Braunschweig, Germany), fixed in 4% paraformaldehyde for 20 min at 4 C, and stained with hematoxylin for 10 min. Blood biochemistry analysis was performed on a Hitachi 911 using kits from Roche (Indianapolis, IN; creatinine, cholesterol, triglycerides, and urea) and Randox (Crumlin, UK; glucose, proteins) and protocols adapted to the small volumes of plasma available from mice. Plasma insulin was determined using the INSIK5 kit (DiaSorin, Inc., Stillwater, MN).


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Production of a mouse population with various degrees of IGF-IR deficiency
We have previously generated a Cre transgenic mouse that produced mosaic-early embryonic ubiquitous Cre-Lox recombination (MeuCre) (Table 1Go). In the early embryo, this line constitutively produced mosaic Cre-mediated recombination patterns very useful for a gene dosage approach (details in Materials and Methods). We crossed this MeuCre line with mice carrying the hypomorphic IGF-IRneolox allele (Fig. 1AGo) (21) following the strategy shown in Fig. 1BGo. As MeuCre also generated mosaicism among germline cells of the F1 double transgenics (with the same efficiency as in other tissues), F2 mice inherited various combinations of IGF-IRneolox, wild-type (WT), and complete KO alleles with or without the MeuCre transgene. This produced a wide spectrum of mutant genotypes in the F2 generation (Fig. 1CGo). To make it possible to deduce the degree of receptor deficiency directly from these genotypes, we measured IGF type I receptor levels in groups of mice with various allelic combinations by receptor-ligand binding assay (Fig. 2Go). The IGF-IRneolox allele produced 40% less receptor than the WT. No receptors were produced from the complete KO allele, and heterozygous KO mice had about half the number of receptors present in normal mice. Various combinations of alleles confirmed that these mutations were essentially not compensated by the sister allele, and that their effects were therefore additive. Thus, the combination of the IGF-IRneolox and IGF-IR KO alleles resulted in 70% receptor deficiency. If such mice had also inherited a MeuCre-transgene, then more than 80% IGF-IR deficiency was possible through additional somatic Cre recombination. As MeuCre is expressed during the early embryonic stages, these acquired receptor deficiencies were considered constitutive for the individual. The degree of IGF receptor deficiency was then determined for all 126 F2 mice directly from their individual allele distributions using phosphorimager data from genomic Southern blots and an appropriate algorithm. As expected, the combined effects of hypomorphic IGF-IRneolox alleles, complete KO alleles, and somatic Cre recombination produced an F2 generation with a wide range of receptor deficiency (Fig. 3AGo). Two large groups of mice, one that displayed moderate levels of deficiency (M) and one with strong deficiency (XS), could be distinguished. Most of the M mice had 10–30% receptor deficiency; most of the XS mice had 70–80% deficiency. XS mice had, on the average, three times fewer receptors per cell than M mice. In this study XS mice were compared with M mice; the latter served as the control group. Although some of the XS animals had more than 80% receptor deficiency, none showed signs of the classical IGF receptor KO phenotype (respiratory insufficiency and neonatal death). Two of the 126 F2 mice died before adulthood, but there was no indication that this was related to their individual degree of receptor deficiency (21% and 45%, respectively).



View larger version (29K):
[in this window]
[in a new window]
 
Figure 2. IGF-I receptor binding as a function of IGF-IR genotype. We tested for the presence of functional IGF-IR in 35 mice with various combinations of mutant alleles using an in vitro receptor ligand binding assay (21 ). For this assay we chose mice that did not harbor MeuCre. Mean values for receptor binding in mice were from 278 fmol/µg total protein in WT mice to undetectable (*) in the complete knockout mice. As complete KO is lethal at birth, we analyzed whole IGF-IR-/- embryos on embryonic d 19; in all other mice, binding was measured in the adult brain tissue. Each IGF-IRneolox allele (NL) reduced receptor binding per cell by 20%; each KO allele reduced receptor binding by about 50%. If mutant alleles were combined, the reduction of receptor levels was additive. We observed no sex-related differences. Inset, IGF receptor binding in preparations from whole embryonic d 19 embryos showed the average receptor dosage in the embryo. This suggested that receptor dosage occurred in the entire embryo and was not restricted to specific (e.g. nervous) tissues.

 


View larger version (21K):
[in this window]
[in a new window]
 
Figure 3. Receptor deficiency and postnatal growth of M and XS mice in the F2. A, Genetically induced receptor deficiency in the F2 ranged from 5–82%. Two large groups were distinguished: 75 mice showing moderate receptor deficiency (M; 0–49%) and 51 mice showing stronger deficiency (XS; 50–100%). We analyzed the growth defects, comparing XS with M mice. B, Differences in mean body weight were observed at 3, 6, and 9 wk between the M and XS groups. Comparison with a WT cohort from an independent experiment at 9 wk of age showed that the postnatal growth of M mice was slightly impaired. Note that the differences between XS and M were significant from 3 wk onward. Levels of significance for the differences between XS and M: *, P < 0.05; **, P < 0.01; ***, P < 0.001 (by Mann-Whitney test). Error bars indicate the SEM.

 
Effects of IGF-IR gene dosage on postnatal growth and IGF system regulation
XS mice weighed significantly less than M littermates from 3 wk after birth onward (Fig. 3BGo). Relative weight differences were stable throughout growth and into adulthood. At 10–12 months, XS males were 78% the weight of M males, and XS females were 86% the weight of their M littermates. The effect of IGF-IR gene dosage on male mice was thus 1.8 times stronger than that on females. The mean plasma IGF-I concentration in the M group (491 ± 28 ng/ml) was normal and similar to that in the WT (490 ± 34 ng/ml); XS mice tended to have lower plasma IGF-I levels (-8%). Plasma levels of IGFBP-1, -2, -3, and -4 were lower than those of M mice; this difference was statistically significant for IGFBP-2 (-21%) and IGFBP-4 (-22%; Table 2Go). One has to bear in mind, however, that Western ligand blotting is a semiquantitative method.


View this table:
[in this window]
[in a new window]
 
Table 2. Mean plasma concentrations of IGF-I (RIA) and IGFBP-1 to IGFBP-4 (Western ligand blotting, WLB) in M and XS males

 
M mice grew slightly less well than wild-type 129/Sv mice raised under the same conditions, and the full effect of IGF-IR gene dosage on tissue-specific growth (see below) would probably have appeared even stronger if XS mice had been compared with a corresponding WT control population. However, we preferred to compare XS directly with M mice, because both groups were issued from the same matings and therefore were a homogeneous population with respect to genetic background, growth cohort, litter size, etc., factors known to affect pre- and postnatal growth and development in mice.

Tissue-specific growth deficits
We dissected 92 of the M and XS mice and found that organs and tissues were affected differently by decreased IGF-IR levels (Table 3Go). We studied all major body compartments and found that bone together with connective tissue (the carcass) and skin were among the most strongly affected tissues. Lung, heart, spleen, and brain were also much reduced in size. The muscle compartment was affected in males, but was less affected in females. Thymus, kidney, and liver were less affected in both sexes (Fig. 4Go). For all of these organs and tissues, the weight reduction in XS mice was concordant in both sexes, but more pronounced in males than in females. The correlation between male and female tissue-specific weight deficits was r2 = 0.30 (P < 0.05) without fat tissue and r2 = 0.91 (P < 0.0001) with fat tissue. We are sure that this result was not due to potential tissue-specific effects of the MeuCre transgene, because we obtained very similar results in F2 mice when all 35 MeuCre-positive individuals were excluded from the 92 dissected animals (results not shown). When we analyzed organ weight relative to body weight, liver and kidney weights increased significantly relative to body weight, whereas the relative weight of fat tissue showed a highly significant decrease in XS mice.


View this table:
[in this window]
[in a new window]
 
Table 3. Tissue-specific weight differences in adult mice with strong (XS) and moderate (M) IGF-I receptor deficiency

 


View larger version (28K):
[in this window]
[in a new window]
 
Figure 4. Effects of IGF-IR gene dosage on organ-specific weight in adult males and females. The mean wet weight of organs and tissues from XS mice was expressed in percent of the M group and plotted on the y-axis (see Table 3Go for numerical data). Results from males (left side) were compared with those from females (right side). Dark shading of boxes indicates that the observed XS/M difference was statistically significant. Error bars (drawn unilaterally for clarity) indicate the SEM. Connecting lines between male and female ratios are drawn in dark gray for those tissues with a sex-linked difference greater than 5%. The proportion of mean total body weight (weight) is indicated by framed boxes. Skin, carcass, spleen, heart, muscle (males only), brain, and lung showed large weight deficits in XS mice. Adipose tissue was the most sensitive tissue to receptor deficiency in both sexes.

 
During early embryogenesis, MeuCre-positive F2 mice produced mosaic tissues composed of cells with various degrees of receptor deficiency. In M mosaics, individual cells showed either 20% (NL) or 50% (heterozygous KO) receptor deficiency. In XS mosaics (i.e. mice with one floxed allele, one KO allele, and MeuCre), individual cells showed either 70% (NL plus KO allele) or 100% (two KO alleles) receptor deficiency. Southern analysis (Fig. 5Go) showed that in M mosaics, many 50% receptor-deficient cells were present in adult tissues together with cells with 20% deficiency. In the adult XS mosaics, however, total KO cells were scarce, suggesting that these cells contributed less to the growth of the tissues and/or that they were less efficiently maintained during growth or afterwards, in the adult tissues. We think that the relative underrepresentation of XS mice with 80–90% reduction in receptor binding in Fig. 3AGo could also be explained by this in vivo cell selection effect.



View larger version (57K):
[in this window]
[in a new window]
 
Figure 5. Cells with a complete loss of both IGF receptor alleles are underrepresented in XS mice. Using DNA extracted from tail biopsy and Southern blotting, a selection of MeuCre-positive mice with the IGF-IRneolox/WT (M) or IGF-IRneolox/KO (XS) genotype were compared. The 3.6-kb band indicates the presence of the {Delta}ex3 allele, which is functionally equivalent to the total KO allele. This allele was present in a significant percentage of cells in tail biopsy samples from M mice (left), but was undetectable in samples from XS mice (right side of the panel). In M cells, the second allele was always WT, whereas in XS cells, it was always KO.

 
We investigated whether organ-specific growth deficits were caused by hypoplasia or hypotrophy by estimating mean cell size using quantitative DNA extraction from tissues. No tissue other than fat tissue (see below) showed significant changes in DNA content per cell (data not shown). We concluded that hypoplasia, rather than hypotrophy, was responsible for low organ weight in muscle, heart, liver, kidney, brain, spleen, and thymus.

Lack of white adipose tissue in IGF-IR insufficiency
Little fat tissue was present in XS mice. The genital fat pad weighed less than 30% in XS males and less than 45% in XS females compared with that in M mice. The data for individual mice (Fig. 6AGo) showed that the mass of the fat pad was distributed very differently in the M and XS populations. The fat pads of M mice showed a large range of sizes (0.1–6 g), with most between 0.1–2 g; the XS mice generally had fat pads weighing less than 1 g, and large fad pads were absent. To estimate cell volume and density in genital fat pads, we extracted adipocyte DNA from M and XS mice. In both sexes, there was significantly less DNA per unit wet weight of adipose tissue from XS mice than from M mice (Table 4Go), indicating that cell volume was larger in XS than in M fat pads. Similar results were obtained even if all individuals with more than 1.3 g adipose tissue were removed from the analysis, so that fad pads of approximately the same size but with different degrees of receptor deficiency were compared.



View larger version (28K):
[in this window]
[in a new window]
 
Figure 6. Characteristics of genital fat pads. A, Weight of the genital fat pad in M and XS males and females. Mean values for each group are indicated with horizontal lines. B, Mice displayed according to the weight of their fat pad and the mean volume of cells in the adipose tissue (calculated from quantitative DNA extraction). {blacksquare}, {square}, Males; •, {circ}, females, M mice are shown in black; XS mice are shown in white. Shaded areas enclose animals of the same sex and group (in terms of receptor deficiency). Note that there is no overlap between XS and M males and little overlap between XS and M females.

 

View this table:
[in this window]
[in a new window]
 
Table 4. Mean cell volume1 in fat tissue (in femtoliter ± SEM) comparing adult males and females with strong (XS) and moderate (M) IGF-I receptor deficiency (b P < 0.05; Mann-Whitney test)

 
Thus, two parameters, mean cell volume and weight of fat pad, clearly distinguished XS and M adipose tissue (Fig. 6BGo). Although the volume of fat cells was significantly greater in XS mice, these mice appeared to be unable to build up larger fat depots. We estimated the number of adipocytes in fat pads of XS males to be 56 x 109 (± 13 x 109) cells, which corresponds to only 21.3% of the mean value for M mice (27.1% for XS females). These figures are probably still an overestimate, because DNA extraction did not differentiate between adipocytes and other cell types present in fat tissue (e.g. blood vessels or connective tissue). Histology confirmed that XS fat tissue was composed of large adipocytes (Fig. 7Go, A–F) and contained very few cell nuclei and large vacuole-like spaces. M adipocytes varied in size, whereas XS fat tissue seemed to be mostly composed of uniformly large adipocytes. We compared tail and fat tissue genotypes in MeuCre-positive F2 mice. Mosaic patterns induced by MeuCre in fat tissue did not differ significantly from that in the tail (an example is shown in Fig. 7GGo), suggesting that fat tissue-specific MeuCre activity was not different from MeuCre activity in other tissues. Fat tissue also showed the same relative lack of complete KO cells as did other tissues.



View larger version (89K):
[in this window]
[in a new window]
 
Figure 7. Effects of IGF-IR deficiency on adult fat tissue. A and B, Abdominal situs with genital fad pad (FP) in XS (A) and M (B) males. C–F, Corresponding histology of fat tissue from XS (C and E) and M (D and F) mice. C and D, Male samples; E and F, female samples. The vacuole-like spaces between adipocyte membranes and cytoplasmic bridges correspond to the lost lipid droplets of several adipocytes. Hematoxylin staining confirmed the data on cell volume obtained by DNA extraction (Table 4Go). G, Southern analysis of genomic DNA from tail and fat tissue. Recombination patterns in MeuCre-positive M and XS mouse samples indicated that early embryonic MeuCre activity was very similar in fat tissue compared with other tissues (represented here by tail DNA). Note that {Delta}ex3 alleles were absent from XS tail and fat samples, similar to results shown in Fig. 5Go. MWM, DNA mol wt marker.

 
Serum creatinine, urea, total protein, cholesterol, and triglycerides were not affected in XS mice. Blood glucose levels were normal in XS females, but significantly lower in XS males (mean ± SEM, 7.2 ± 0.6 in XS males vs. 9.7 ± 0.5 mmol/liter in M males; P < 0.01). Nonfasting plasma insulin levels were within the normal range for the M males and the M and XS females (25.7 ± 3.6 µIU/ml). In contrast, XS males had significantly lower plasma insulin concentrations (16.6 ± 2.3 µIU/ml; P < 0.05).


    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The IGF-I receptor gene is biallelically expressed in mice. Combinations of mutant receptor alleles (e.g. partial deficiency of one allele with total deficiency of the second allele, or partial deficiency of both alleles) had additive effects in terms of the decrease in number of cell surface IGF-I receptors. This suggests that IGF-I receptor deficiency does not induce significant allelic regulation. This is consistent with the recent finding (33) that classical IGF-IR KO mice display a growth deficiency phenotype in the heterozygous state, but not with the original finding of Liu et al. (12) that heterozygous receptor KO mice show normal receptor expression and normal growth. Clearly, the Cre-lox gene targeting used here does not result in significant up-regulation of receptor production even if the number of IGF-IR at the cell surface is only 20–30% of WT levels. It is unclear whether this is related to the structure of the mature transcripts, which can be deduced for the various forms of targeted alleles used here. The wild-type IGF-IR allele produces an 11-kb mRNA containing large 5'- and 3'-untranslated regions. The IGF-IRneolox allele produces mature transcripts that contains, in 40% of cases, short RNA insertions from the neo-cassette, which cause receptor deficiency at the translational level (21). The Cre-lox induced KO allele also produces an intact mRNA, except that it lacks the 313-nucleotide region encoding exon 3. In this case, receptor deficiency occurs at the translational level due to a frameshift at the exon 2/exon 4 junction. IGF-IR thereby ends with lysine183, is followed by a 27-amino acid nonsense peptide, and is terminated by a new stop codon (nucleotides 84–86 of mouse exon 4). In the conventional KO alleles, to the contrary, the open reading frame of the IGF-IR gene had been interrupted by an exonic neo-cassette insertion, leading to mRNAs truncated at exon 3.

Adult XS mice with about one quarter the number of receptors present in normal mice were viable and fertile. However, consistent with previous findings (21), this level of receptor deficiency significantly impaired the postnatal and, in particular, pubertal growth of male and female mice. We conclude that two functional receptor alleles are necessary for normal postnatal growth. The growth retardation did accumulate during prepuberty and puberty. No significant catch-up growth was observed in XS mice after puberty, as it has been reported for the double IGF-IR/M6P-R(IGF-IIR)-KO mutant (34). Male XS mice in this study reached 70% of WT weight, and their growth retardation was therefore less severe than that of classical IGF-I KO mice (~30% of adult WT weight) (12). This suggests that in XS mice, the remaining 20–30% receptors mediate more than half of the IGF-dependent postnatal weight gain.

The sexual dimorphism of pubertal growth depends on the IGF-IR
In XS mice with low functional IGF-IR levels, much of the normal sex-related postnatal growth dimorphism had disappeared. Androgens and estrogens are the most likely candidates for regulating sexually dimorphic growth in puberty and postpuberty. However, direct evidence implicating these hormones in body growth is scarce. GH secretion patterns, on the other hand, are sexually dimorphic, showing solid regular peaks and low intermediate levels in males and more frequent peaks with higher intermediate levels in females (35). However, it is not known in detail how these dimorphic secretion patterns generate divergent growth in males and females. GH-dependent, hepatic IGF-I production does not seem to be involved, because in a number of mammalian species, circulating IGF-I levels are clearly not correlated with sex-linked differences in somatic development (36). As the IGF receptor seems to mediate at least part of the additional growth of males (Ref. 21 and results reported here), we believe that the causes of sexually dimorphic growth differences are probably situated at the level of the target cell. Local IGF-I production, which is known to have determining effects on body growth (6), may be regulated by androgens and/or estrogens, or androgens may cooperate with IGF signaling in target tissues. This would result in higher levels of IGF signaling, regulated on a paracrine/autocrine basis, with no change in the total circulating IGF concentration.

In the IGF-IR knockdown model, the growth of males was more retarded than that of females, whereas IGF-I was up-regulated, and IGFBP-4 was down-regulated. As greater receptor deficiency was observed in the present model than in the knockdown model, we expected the IGF-I concentration to be high. Circulating IGF ligand levels were, however, similar to or even lower than normal levels. As the IGF-I concentration is high in fat tissue (37, 38), it is possible that the significant lack of adipocytes in XS mice may have counteracted, to some degree, any underlying physiological up-regulation of IGF-I. In addition, IGFBP levels tended to be lower in XS mice, which also might lower the circulating IGF-I concentration in the adult. Plasma concentrations of IGFBP-2, IGFBP-3, and IGFBP-4 were significantly correlated with IGF-I levels. Finally, the down-regulation of IGFBP-4, here accompanied by a significant decrease in IGFBP-2, seems to be a consistent trait in IGF type I receptor deficiency. As IGF-I and IGFBP-3 levels are known to be normal in some human growth retardations, it may be interesting to study IGFBP-4 in these conditions.

Studies using transgenic mice suggested that IGFBP-4 is a functional antagonist of IGF-I in vivo (39). The low IGFBP-4 (and IGFBP-2) levels observed in our study could thus be a regulatory response by which IGF-IR-deficient XS males try to increase growth. Transgenic overexpression of IGF-I, although increasing IGFBP-5 production, did not alter IGFBP-4 levels (40). This indicated that regulation of IGFBP-4 may not be secondary to changes in circulating IGF-I levels (in the present study IGF-I levels of XS males were not significantly altered), but could be more directly related to reduced levels of IGF-IR (21). Clearly, further experiments are needed to clarify some of these important points concerning IGF system regulation.

Organ-specific effects of ubiquitous IGF-IR deficiency
We show here that receptor deficiency created a sexdimorphic growth deficit that affected various tissues to different degrees. Body compartments, such as bone and cartilage, muscle, and skin, which are often not directly evaluated, showed the strongest effects. In contrast, other organs, such as the heart, liver, and kidney, showed relatively small effects. In XS males, there was only about one quarter the normal amount of fat tissue, indicating a high sensitivity to IGF receptor deficiency.

We found a significant correlation between male and female tissue-specific growth deficits. In both sexes, tissues showed either a strong growth deficit (adipose tissue, skin, heart, lung, bone, cartilage and connective tissue, spleen, and brain) or a weak deficit (kidney, thymus, and liver). Some tissues or organs, however, showed sex-specific growth deficits (bone, cartilage and connective tissues, spleen, muscle, and liver). These results were consistent with findings for the classical IGF receptor KO, in which the principal neonatal defects concerned skin, brain, skeleton, lung, and muscle (12). Our observations are also consistent with results from other studies (reviewed in Ref. 2), in that the degree of organ and/or tissue growth retardation in IGF-IR-deficient mice corresponds well to the magnitude of overgrowth in IGF-I overproducing mice, indicating the tissues whose growth is especially dependent on IGF signaling, such as heart, brain, skin, muscle, cartilage, and bone. A particular advantage of the present model over tissue-specific ligand overproduction, however, is that the genetically fixed receptor deficiency allows comparison of the IGF sensitivities of multiple tissues in a single experimental animal.

Adipose tissue
We observed a strong growth deficit in fat tissue. Interestingly, fat tissue produces large amounts of IGF-I (even when compared with synthesis in the liver). In addition, this IGF-I production is GH dependent, and preadipocytes are sensitive to IGF-I signaling (37). Moreover, preadipocytes produce significant amounts of IGF-IR, whereas mature adipocytes do not (41). Our findings are compatible with the idea that the IGF-I produced by fat tissue may have major paracrine and autocrine functions during the ontogenesis of fat tissue. Cell culture studies on the proliferation of adipocyte precursor cells and their differentiation into mature adipocytes have identified IGFs as important regulators of adipocyte development (42, 43). Experiments using primary cultures of adipocyte precursors have shown that IGFs increase the proliferation of these precursors and inhibit terminal adipocyte differentiation (44). A similar mechanism could explain the reduction in size of the adipocyte compartment in XS mice, through limitation of adipocyte precursor proliferation in vivo and stimulation of differentiation into mature adipocytes.

Our findings are consistent with recent in vivo studies by Rajkumar et al. (45), who investigated adipogenesis in IGFBP-1-overproducing transgenic mice. No significant difference in fat pad development was observed between IGFBP-1-overproducing mice and WT mice fed a normal diet. However, if the mice were fed a diet rich in glucose, IGFBP-1-overproducing mice were less able than wild-type mice to increase their fat tissue. In contrast to our findings, however, adipocytes in IGFBP-1-overproducing mice were smaller than cells in wild-type mice. These researchers found evidence that IGFBP-1-overproducing fat tissue is less able to generate adipocyte colonies in primary culture. This is consistent with there being a defect in preadipocyte proliferation and adipocyte differentiation due to impaired IGF signaling. Complete insulin receptor deficiency has also been found to affect the formation of adipose tissue in mice (46), suggesting that insulin and IGFs may finally both be involved in the control of fat tissue development.


    Acknowledgments
 
We thank Hermann Bujard and Werner Müller for plasmids, Dominique Daegelen for providing access to the microinjection facilities at the Institut Cochin de Génétique Moléculaire (Paris, France), Philippe Monget for critical reading of the manuscript, and Julie Sappa for language revision. We are indebted to Frédérique Veinberg for blood biochemistry analysis.


    Footnotes
 
This work was supported by INSERM, Ministère de l’Education Nationale, Recherche et Technologie, Association Française contre les Myopathies, and the University of Paris VI (Faculté de Médecine Saint Antoine).

1 Fellow of Novo Nordisk (France). Back

Abbreviations: IGFBP, IGF-binding protein; IGF-IR, IGF type I receptor; KO, knockout; M, moderate IGF type I receptor deficiency; MeuCre, mosaic-early embryonic-ubiquitous Cre transgene; NL, neolox; rhIGF, recombinant human IGF-I; WT, wild-type; XS, strong (>=50%) IGF type I receptor deficiency.

Received May 10, 2001.

Accepted for publication July 3, 2001.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. De Chiara TM, Efstratiadis A, Robertson EJ 1990 A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature. 345:78–80
  2. D’Ercole AJ 1999 Actions of IGF system proteins from studies of transgenic and gene knockout models. In: Rosenfeld R, Roberts Jr C, eds. The IGF system. Totowa: Humana Press; 545–577
  3. Blakesley VA, Butler AA, Koval AP, Okubo Y, LeRoith D 1999 IGF-I receptor function: transducing the IGF-I signal into intracellular events. In: Rosenfeld R, Roberts Jr C, eds. The IGF system. Totowa: Humana Press; 143–164
  4. Werner H 1999 Molecular biology of the type I IGF receptor. In: Rosenfeld R, Roberts Jr C, eds. The IGF system. Totowa: Humana Press; 63–88
  5. Liu JL, Grinberg A, Westphal H, et al. 1998 Insulin-like growth factor-I affects perinatal lethality and postnatal development in a gene dosage-dependent manner: manipulation using the Cre/loxP system in transgenic mice. Mol Endocrinol 12:1452–1462[Abstract/Free Full Text]
  6. Yakar S, Liu JL, Stannard B, et al. 1999 Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 96:7327–7329
  7. Sjögren K, Liu JL, Blad K, et al. 1999 Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci USA 96:7088–7092[Abstract/Free Full Text]
  8. Kühn R, Schwenk F, Aguet M, Rajewsky K 1995 Inducible gene targeting in mice. Science 269:1427–1429[Abstract/Free Full Text]
  9. Marth JD 1996 Recent advances in gene mutagenesis by site-directed recombination. J Clin Invest 97:1999–2002[Medline]
  10. Müller U 1999 Ten years of gene targeting: targeted mouse mutants, from vector design to phenotype analysis. Mech Dev 82:3–21[CrossRef][Medline]
  11. Holzenberger M, Hamard G, Leneuve P, et al. 1999 Partial invalidation and dosage of the IGF type 1 receptor gene via homologous and Cre-lox recombination results in postnatal proportionate dwarfism [Abstract]. Growth Hormone IGF Res 9:308–309[Medline]
  12. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A 1993 Mice carrying null mutations of the genes encoding insulin-like growth factor I (IGF-1) and type 1 IGF receptor (Igf1r). Cell 75:59–72[Medline]
  13. Baker J, Liu J-P, Robertson EJ, Efstratiadis A 1993 Role of insulin-like growth factors in embryonic and postnatal growth. Cell 75:73–82[CrossRef][Medline]
  14. Powell-Braxton L, Hollingshead P, Warburton C, et al. 1993 IGF-I is required for normal embryonic growth in mice. Genes Dev 7:2609–2617[Abstract/Free Full Text]
  15. Powell-Braxton L, Hollingshead P, Giltinan D, Pitts-Meek S, Stewart T 1993 Inactivation of the IGF-I gene in mice results in perinatal lethality. Ann NY Acad Sci 692:300–301[CrossRef][Medline]
  16. Beck KD, Powell-Braxton L, Widmer HR, Valverde J, Hefti F 1995 Igf1 gene disruption results in reduced brain size, CNS hypomyelination, and loss of hippocampal granule and striatal parvalbumin-containing neurons. Neuron 14:717–730[CrossRef][Medline]
  17. Wang J, Zhou J, Powell-Braxton L, Bondy C 1999 Effects of Igf1 gene deletion on postnatal growth patterns. Endocrinology 140:3391–3394[Abstract/Free Full Text]
  18. Carson MJ, Behringer RR, Brinster RL, McMorris FA 1993 Insulin-like growth factor I increases brain growth and central nervous system myelination in transgenic mice. Neuron 10:729–740[CrossRef][Medline]
  19. Coleman ME, DeMayo F, Yin KC, et al. 1995 Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J Biol Chem 270:12109–12116[Abstract/Free Full Text]
  20. Reiss K, Cheng W, Ferber A, et al. 1996 Overexpression of IGF-I in the heart is coupled with myocyte proliferation in transgenic mice. Proc Natl Acad Sci USA 93:8630–8635[Abstract/Free Full Text]
  21. Holzenberger M, Leneuve P, Hamard G, et al. 2000 A targeted partial invalidation of the insulin-like growth factor I receptor gene in mice causes a postnatal growth deficit. Endocrinology 141:2557–2566[Abstract/Free Full Text]
  22. Nagy A, Moens C, Ivanyi E, et al. 1998 Dissecting the role of N-myc in development using a single targeting vector to generate a series of alleles. Curr Biol 8:661–664[CrossRef][Medline]
  23. Nagy A 2000 Cre recombinase: the universal reagent for genome tailoring. Genesis 26:99–109[CrossRef][Medline]
  24. Hogan B, Beddington R, Constantini F, Lacy E 1994 Manipulating the mouse embryo, 2nd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 226–247
  25. Baron U, Freundlieb S, Gossen M, Bujard H 1995 Co-regulation of two gene activities by tetracycline via a bidirectional promoter. Nucleic Acids Res 23:3605–3606[Free Full Text]
  26. Dietrich P, Dragatsis I, Xuan S, Zeitlin S, Efstratiadis A 2000 Conditional mutagenesis in mice with heat shock promoter-driven cre transgenes. Mamm Genome 11:196–205[CrossRef][Medline]
  27. Hogan B, Beddington R, Constantini F, Lacy E 1994 Manipulating the mouse embryo, 2nd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 296–298
  28. Durieux C, Ruiz-Gayo M, Corringer PJ, Bergeron F, Ducos B, Roques BP 1992 [3H]pBC 264, a suitable probe for studying cholecystokinin-B receptors: binding characteristics in rodent brains and comparison with [3H]SNF 8702. Mol Pharmacol 41:1089–1095[Abstract]
  29. Gay E, Seurin D, Babajko S, Doublier S, Cazillis M, Binoux M 1997 Liver-specific expression of human insulin-like growth factor binding protein-1 in transgenic mice: repercussions on reproduction, ante- and perinatal mortality and postnatal growth. Endocrinology 138:2937–2947[Abstract/Free Full Text]
  30. Bessone S, Vidal F, Le Bouc Y, Epelbaum J, Bluet-Pajot MT, Darmon M 1999 EMK protein kinase-null mice: dwarfism and hypofertility associated with alterations in the somatotrope and prolactin pathways. Dev Biol 214:87–101[CrossRef][Medline]
  31. Binoux M, Seurin D, Lassarre C, Gourmelen M 1984 Preferential measurement of insulin-like growth factor (IGF) I-related peptides in serum with the aid of IGF binding proteins (IGFBPs) produced by rat liver in culture. Estimation of serum IGFBP levels. J Clin Endocrinol Metab 59:453–462[Abstract]
  32. Hossenlopp P, Seurin D, Segovia-Quinson B, Hardouin S, Binoux M 1986 Analysis of serum insulin-like growth factor binding proteins using western blotting: use of the method for titration of the binding protein and competitive binding studies. Anal Biochem 154:138–143[CrossRef][Medline]
  33. Withers DJ, Burks DJ, Towery HH, Altamuro SL, Flint CL, White MF 1999 Irs-2 coordinates Igf-1 receptor-mediated ß-cell development and peripheral insulin signalling. Nat Genet 23:32–39[Medline]
  34. Ludwig T, Eggenschwiler J, Fisher P, D’Ercole AJ, Davenport ML, Efstratiadis A 1996 Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in Igf2 and Igf1r null backgrounds. Dev Biol 177:517–535[CrossRef][Medline]
  35. Mauras N, Rogol AD, Haymond MW, Veldhuis JD 1996 Sex steroids, growth hormone, insulin-like growth factor-1: neuroendocrine and metabolic regulation in puberty. Horm Res 45:74–80[Medline]
  36. Gatford KL, Egan AR, Clarke IJ, Owens PC 1998 Sexual dimorphism of the somatotrophic axis. J Endocrinol 157:373–389[CrossRef][Medline]
  37. Peter MA, Winterhalter KH, Boni-Schnetzler M, Froesch ER, Zapf J 1993 Regulation of insulin-like growth factor-I (IGF-I) and IGF-binding proteins by growth hormone in rat white adipose tissue. Endocrinology 133:2624–2631[Abstract]
  38. D’Ercole AJ, Stiles AD, Underwood LE 1984 Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci USA 81:935–939[Abstract/Free Full Text]
  39. Wang J, Niu W, Witte DP, et al. 1998 Overexpression of insulin-like growth factor-binding protein-4 (IGFBP-4) in smooth muscle cells of transgenic mice through a smooth muscle {alpha}-actin-IGFBP-4 fusion gene induces smooth muscle hypoplasia. Endocrinology 139:2605–2614[Abstract/Free Full Text]
  40. Ye P, D’Ercole J 1998 Insulin-like growth factor I (IGF-I) regulates IGF binding protein-5 gene expression in the brain. Endocrinology 139:65–71[Abstract/Free Full Text]
  41. Smith PJ, Wise LS, Berkowitz R, Wan C, Rubin CS 1988 Insulin-like growth factor-I is an essential regulator of the differentiation of 3T3–L1 adipocytes. J Biol Chem 263:9402–9408[Abstract/Free Full Text]
  42. Wabitsch M, Hauner H, Heinze E, Teller WM 1995 The role of growth hormone/insulin-like growth factors in adipocyte differentiation. Metabolism 44:45–49[CrossRef][Medline]
  43. Richelsen B 1997 Action of growth hormone in adipose tissue. Horm Res 48(Suppl 5):105–110
  44. Kras KM, Hausman DB, Hausman GJ, Martin RJ 1999 Adipocyte development is dependent upon stem cell recruitment and proliferation of preadipocytes. Obes Res 7:491–497[Medline]
  45. Rajkumar K, Modric T, Murphy LJ 1999 Impaired adipogenesis in insulin-like growth factor binding protein-1 transgenic mice. J Endocrinol 162:457–465[Abstract]
  46. Cinti S, Eberbach S, Castellucci M, Accili D 1998 Lack of insulin receptor affects the formation of white adipose tissue in mice. A morphometric and ultrastructural analysis. Diabetologia 41:171–177[CrossRef][Medline]



This article has been cited by other articles:


Home page
Cancer Res.Home page
B. W. Sutherland, S. E. Knoblaugh, P. J. Kaplan-Lefko, F. Wang, M. Holzenberger, and N. M. Greenberg
Conditional Deletion of Insulin-like Growth Factor-I Receptor in Prostate Epithelium
Cancer Res., May 1, 2008; 68(9): 3495 - 3504.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
J. A. Duffield, T. Vuocolo, R. Tellam, B. S. Yuen, B. S. Muhlhausler, and I. C. McMillen
Placental restriction of fetal growth decreases IGF1 and leptin mRNA expression in the perirenal adipose tissue of late gestation fetal sheep
Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2008; 294(5): R1413 - R1419.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. B. Hurov, M. Huang, L. S. White, J. Lennerz, C. S. Choi, Y.-R. Cho, H.-J. Kim, J. L. Prior, D. Piwnica-Worms, L. C. Cantley, et al.
Loss of the Par-1b/MARK2 polarity kinase leads to increased metabolic rate, decreased adiposity, and insulin hypersensitivity in vivo
PNAS, March 27, 2007; 104(13): 5680 - 5685.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
J Svensson, M Diez, J Engel, C Wass, A Tivesten, J-O Jansson, O Isaksson, T Archer, T Hokfelt, and C Ohlsson
Endocrine, liver-derived IGF-I is of importance for spatial learning and memory in old mice.
J. Endocrinol., June 1, 2006; 189(3): 617 - 627.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
K. Raile, J. Klammt, A. Schneider, A. Keller, S. Laue, R. Smith, R. Pfaffle, J. Kratzsch, E. Keller, and W. Kiess
Clinical and Functional Characteristics of the Human Arg59Ter Insulin-Like Growth Factor I Receptor (IGF1R) Mutation: Implications for a Gene Dosage Effect of the Human IGF1R
J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2264 - 2271.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
M. Sadagurski, S. Yakar, G. Weingarten, M. Holzenberger, C. J. Rhodes, D. Breitkreutz, D. LeRoith, and E. Wertheimer
Insulin-like growth factor 1 receptor signaling regulates skin development and inhibits skin keratinocyte differentiation.
Mol. Cell. Biol., April 1, 2006; 26(7): 2675 - 2687.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
J. Svensson, B. Soderpalm, K. Sjogren, J. Engel, and C. Ohlsson
Liver-derived IGF-I regulates exploratory activity in old mice
Am J Physiol Endocrinol Metab, September 1, 2005; 289(3): E466 - E473.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
X.-J. Du
Gender modulates cardiac phenotype development in genetically modified mice
Cardiovasc Res, August 15, 2004; 63(3): 510 - 519.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
S. Unger, S. D. Chernausek, W. Kiess, and R. J. Smith
IGF-I Receptor Mutations and Intrauterine and Postnatal Growth Retardation
N. Engl. J. Med., March 25, 2004; 350(13): 1362 - 1363.
[Full Text]